| Event . | Patients [n = 45] . |
|---|---|
| Total number of AEs | 15 |
| Total number of unique patients with AEs | 12 [27%] |
| Dyslipidaemia | 3 [7%] |
| Leukopaenia | 1 [2%] |
| Elevated liver tests | 3 [7%] |
| Malignancy | 0 [0%] |
| Infection | |
| All infectious complications | 1 [3%] |
| Zoster infection | 0 [0%] |
| Tuberculosis and other opportunistic infection | 0 [0%] |
| Other non-serious adverse events | 5 [11%] |
| Serious adverse events | |
| Cardiovascular event | 1 [3%] |
| Hospitalization | 1 [3%] |
| Intestinal perforation | 0 [0%] |
| Mortality | 0 [0%] |
| Event . | Patients [n = 45] . |
|---|---|
| Total number of AEs | 15 |
| Total number of unique patients with AEs | 12 [27%] |
| Dyslipidaemia | 3 [7%] |
| Leukopaenia | 1 [2%] |
| Elevated liver tests | 3 [7%] |
| Malignancy | 0 [0%] |
| Infection | |
| All infectious complications | 1 [3%] |
| Zoster infection | 0 [0%] |
| Tuberculosis and other opportunistic infection | 0 [0%] |
| Other non-serious adverse events | 5 [11%] |
| Serious adverse events | |
| Cardiovascular event | 1 [3%] |
| Hospitalization | 1 [3%] |
| Intestinal perforation | 0 [0%] |
| Mortality | 0 [0%] |
AEs, adverse events.
| Event . | Patients [n = 45] . |
|---|---|
| Total number of AEs | 15 |
| Total number of unique patients with AEs | 12 [27%] |
| Dyslipidaemia | 3 [7%] |
| Leukopaenia | 1 [2%] |
| Elevated liver tests | 3 [7%] |
| Malignancy | 0 [0%] |
| Infection | |
| All infectious complications | 1 [3%] |
| Zoster infection | 0 [0%] |
| Tuberculosis and other opportunistic infection | 0 [0%] |
| Other non-serious adverse events | 5 [11%] |
| Serious adverse events | |
| Cardiovascular event | 1 [3%] |
| Hospitalization | 1 [3%] |
| Intestinal perforation | 0 [0%] |
| Mortality | 0 [0%] |
| Event . | Patients [n = 45] . |
|---|---|
| Total number of AEs | 15 |
| Total number of unique patients with AEs | 12 [27%] |
| Dyslipidaemia | 3 [7%] |
| Leukopaenia | 1 [2%] |
| Elevated liver tests | 3 [7%] |
| Malignancy | 0 [0%] |
| Infection | |
| All infectious complications | 1 [3%] |
| Zoster infection | 0 [0%] |
| Tuberculosis and other opportunistic infection | 0 [0%] |
| Other non-serious adverse events | 5 [11%] |
| Serious adverse events | |
| Cardiovascular event | 1 [3%] |
| Hospitalization | 1 [3%] |
| Intestinal perforation | 0 [0%] |
| Mortality | 0 [0%] |
AEs, adverse events.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
